An Open Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetics and Tumor Growth Control Rate of RO5083945, a Glycoengineered Antibody Against EGFR, in Patients With Metastatic and/or Locally Advanced Malignant EGFR+ Solid Tumors.

Trial Profile

An Open Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetics and Tumor Growth Control Rate of RO5083945, a Glycoengineered Antibody Against EGFR, in Patients With Metastatic and/or Locally Advanced Malignant EGFR+ Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Imgatuzumab (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Planned end date changed from 1 Jan 2012 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 18 Apr 2011 Planned End Date changed from 1 Jun 2011 to 1 Jan 2012, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top